Table 4.
Grade 3 or Higher Adverse Events.
| TACE + lenvatinib + PD-1 inhibitors (n = 23) | TACE + lenvatinib (n = 32) | TACE + sorafenib (n = 29) | P-value | |
|---|---|---|---|---|
| Elevated ALT | 5 (21.74) | 6 (18.75) | 6 (20.69) | .961 |
| Elevated AST | 4 (17.39) | 7 (21.88) | 4 (13.79) | .711 |
| Hypertension | 1 (4.35) | 1 (3.13) | 0 (0.00) | .558 |
| Nausea | 1 (4.35) | 2 (6.25) | 0 (0.00) | .411 |
| Diarrhea | 1 (4.35) | 1 (3.13) | 1 (3.45) | .970 |
| Fatigue | 1 (4.35) | 1 (3.13) | 1 (3.45) | .970 |
| Rash | 0 (0.00) | 0 (0.00) | 1 (3.45) | .383 |
| Hand-foot syndrome | 0 (0.00) | 0 (0.00) | 2 (6.70) | .143 |
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; RECIST, modified response evaluation criteria in solid tumors; PD-1, programmed death 1; TACE, transarterial chemoembolization.